Summary
E-cadherin is a cell-cell adhesion molecule involved in epithelial cell behavior, tissue formation and cancer suppression. In the liver, E-cadherin is expressed by hepatocytes and biliary epithelial cells. The precise role of this protein in hepatic pathophysiology remains largely unknown. Recently, loss of E-cadherin in liver epithelial cell types has been shown to lead to periportal fibrosis and inflammation and to promote liver carcinogenesis.
Cell junctions, such as tight junctions and adherens junctions, organize and protect epithelia.
E-cadherin, a major constituent of adherens junctions, establishes cell-cell interactions in epithelia but also participates in several cellular processes such as differentiation and cell signaling [1] . In liver, E-cadherin is expressed by hepatocytes and biliary epithelial cells, however its involvement in hepatic pathophysiology remains largely unknown [2] The establishment of cell junctions between epithelial cells is crucial for the normal organization of liver functions, such as bile secretion [1] . Consistently, alterations in tight junctions have been related to cholestatic liver diseases, such as the neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome [3] , primary biliary cirrhosis (PBC) and PSC [4] .
Furthermore, expression of E-cadherin may also be altered in the liver of patients with arthrogryposis, renal dysfunction and cholestasis (ARC) [5] , a syndrome for which liver features include paucity of bile ducts, cholestasis and mild inflammation [6] . We have recently shown that, during experimental bile duct obstruction, adherens junctions were altered by the expression of a truncated form of E-cadherin. Furthermore, our data indicate that liver injury was exacerbated when the truncated E-cadherin expression was increased [7] .
Here, Nakagawa et al. show that the absence of hepatic E-cadherin leads to a cholestatic phenotype evocative of PSC. Adherens junctions in hepatocytes and biliary epithelial cells
were not altered in 2-month old CDH1 ∆L mice, as shown by electronic microscopy analysis.
However, bile acid secretion into bile ducts was impaired in these mice. The latter observation could reflect adaptive mechanisms able to compensate for adherens junctions organization but 6 not for E-cadherin signaling functions. In this context, the analysis of the expression and localization of transporters in hepatocytes and biliary epithelial cells would be valuable. In the adult mouse liver, E-cadherin expression is restricted to peri-portal hepatocytes, while in perivenous hepatocytes N-cadherin is expressed [8] . Because E-cadherin and N-cadherin zonation takes place after birth [8] , N-cadherin could compensate for the hepatic absence of Ecadherin. Furthermore, adherens junctions morphological analysis was performed in 2-month old animals while the cholestatic phenotype was evident at 8-month of age (ALP levels, histology). Thus, altered adherens junctions morphology may appear later in the CDH1 ∆L mice as we have previously shown that E-cadherin alterations were increased when cholestasis was established in Vdr -/-mice [7] .
CDH1
∆L mice show signs of ductular reaction and portal inflammation at 2-month of age. The latter observations may account for the inflammatory and proliferative effects of bile acids on liver cells [9, 10] . However, eight weeks after E-cadherin expression was specifically suppressed in hepatocytes, no sign of portal inflammation or ductular reaction could be evidenced. In contrast, specific invalidation of E-cadherin in biliary epithelial cells was associated with portal inflammation and ductular reaction. Consistently, mice invalidated for hepatic E-cadherin that maintain E-cadherin expression in non-hepatocyte cells do not show ductular proliferation and portal fibrosis [11] . Thus, accumulation of bile acids in the portal space may be the first trigger inducing inflammation and proliferation of biliary epithelial cells. Proliferating biliary epithelial cells devoid of E-cadherin may be unable to assemble new adherens junctions, as previously described in other epithelial cells [12] , leading to the formation of leaky bile ducts. Leaky bile ducts would then favor the release of toxic compounds, such as bile acids and endotoxins, from bile. The latter would lead to the recruitment of macrophages that are major inducers of the ductular reaction through the 7 release of inflammatory cytokines (i.e. IL-6). Thus, a vicious circle of inflammation and proliferation is set by the absence of E-cadherin in the portal space.
The ductular reaction observed in CDH1 ∆L mice was associated with an increased expression of K19. The over-expression of K19 is indicative of biliary epithelial cell proliferation, but also of the presence of bi-potential hepatic progenitor cells. Bi-potential hepatic progenitor cells have the ability to differentiate either into hepatocytes or biliary epithelial cells [13] and may be involved in the development of HCC and CCC [14] . [15] [16] [17] . In CCC cells, E-cadherin colocalizes with EGFR [18] , while E-cadherin displays inhibitory activities towards EGFR [17] . Thus, absence of E-cadherin may favor cell proliferation, migration and invasion by activating EGFR pathways [17, 19, 20] . Furthermore, we have recently shown that CCC cells produce TGF-1 that in turn activates myofibroblasts from the tumor stroma. These myofibroblasts will produce HB-EGF that in a paracrine loop activates EGFR on CCC cells [21] . Thus, the absence of E-cadherin in biliary epithelial cells should activate the EGFR pathway leading to TGF-1 production. TGF-1 will increase HB-EGF production by mesenchymal cells of the portal space that will in turn favor biliary epithelial cell proliferation and EMT through EGFR signaling [22] [23] [24] . Interestingly, the observation of CCC tumors in mice lacking hepatic E-cadherin recapitulates the 8 pathophysiological continuum of PSC, a well-known pathology associated with CCC development [25] .
In conclusion, Nakagawa et al. show that dysregulation of E-cadherin expression in epithelial liver cells is sufficient to induce portal fibrosis and liver cancer. Even though it is still unclear how the specific absence of E-cadherin leads to a PSC-like phenotype, the demonstration that PSC may arise solely from biliary epithelial cells is a disruptive concept. Finally, the authors also demonstrate that the absence of E-cadherin in liver epithelial cells favors carcinogenesis and intrahepatic metastasis. The origin of these tumors needs however further clarifications.
Taken together, the observations of Nakagawa et al. suggest that stabilization of adherens junctions in epithelial liver cells may prevent inflammatory biliary disease and liver cancer.
